Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma
Giglio P et al. – The combination of thalidomide and irinotecan did not achieve sufficient efficacy to warrant further investigation against anaplastic gliomas (AGs), although a subset of patients experienced prolonged progression–free survival (PFS)/overall survival (OS). A trial of the more potent thalidomide analogue, lenalidomide, in combination with irinotecan against AG is currently ongoing.
Adults with recurrent AG previously treated with radiation therapy, with Karnofsky performance score ≥70, adequate organ function and not on enzyme-inducing anticonvulsants were enrolled.
Treatment was in 6-week cycles with irinotecan at 125mg/m2 weekly for 4weeks followed by 2weeks off, and thalidomide at 100mg daily increased to 400mg/day as tolerated.
The primary endpoint was progression-free survival rate at 6months (PFS-6), and the secondary endpoints were overall survival (OS) and response rate (RR).
In 39 eligible patients, PFS-6 for the intent-to-treat population was 36% (95% confidence interval [CI]=21%, 53%), median PFS was 13weeks (95% CI=6%, 28%) and RR was 10%(95% CI=3%, 24%).
Radiological findings included 2 complete and 2 partial responses and 17 stable disease.
Median OS from study registration was 62weeks, (95% CI=51, 144).
Treatment-related toxicities (grade 3 or higher) included neutropenia, diarrhea, nausea, and fatigue; 6 patients experienced venous thromboembolism.
Four deaths were attributable to treatment-related toxicities: 1 from pulmonary embolism, 2 from colitis, and 1 from urosepsis.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.